Casually stepped outside and boom—northern light 🌌✨

Check out the latest #APS Program Update showcasing the lab's latest news & achievements, their upcoming presentations at #ACR24, and recent lectures, including the presentations given at the APS Research Conversation & Lab Tour they hosted in October. conta.cc/48sIWdI

Yikes we have a lot of people presenting at #ACR24 this year. Way to go Michigan APS team 〽️🫡

Read the new #APS Program Update that includes the lab's latest news & achievements, recordings of their recent lectures & talks, #ACR24 highlights, and What I’m Reading in APS Research written by Dr. Ajay Tambralli. conta.cc/4ird0vb

On my way to the Deep South for an exciting day of rheumatology tomorrow 🧐

Read the latest #APS Program Update that features Dr. Jacqueline Madison's participation at the Pediatric APS Consensus Conference, APS Program Community Q&A Series on GLP-1 drugs by Dr. Yu (Ray) Zuo & Dr. Lauren Shevell & Q&A from Dr. Jason S Knight's inbox. conta.cc/4hKpI7f

Can GLP-1 agonists be considered for weight loss in patients with #APS? Yu (Ray) Zuo highlights that while data is limited, early evidence shows GLP-1 receptor agonists do not appear to increase thrombotic risk & may help reduce inflammation: cutt.ly/prpCC327 Michigan Medicine

🚨 New from our lab! 🚨 Neutrophil calprotectin—once just a NET marker—is now unmasked as a powerful predictor of future heart disease 💔🧬U-M Department of Internal Medicine APS Support UK Taubman Institute Jason S Knight ➡️ michiganmedicine.org/health-lab/how… #CardioTwitter #RheumTwitter #Atherosclerosis 🫀🧪

Research shows #calprotectin, a marker of #NeutrophilActivation, as a potential early indicator of #AtheroscleroticCardiovascularDisease. Elevated calprotectin levels were shown to predict future #HeartDisease risk, even in individuals without symptoms: cutt.ly/arx5jbId

June is #APSAwareness Month! Check out the latest APS Program Update, featuring our investigators in a special article with APS Foundation of America, add'l news & achievements, a patient's story about living with APS & What I’m Reading in APS Research by Dr. Ajay Tambralli. conta.cc/4jUou9U

Catastrophic antiphospholipid syndrome completely transformed Mark Hall’s daily life. But access to comprehensive care at U-M Health has been pivotal in treating his condition and redefining what it means to live with APS. Read Mark's story on our blog: michmed.org/JDkYV

A great story showcasing the cutting-edge work coming out of the #APS Program and the APS Research Labs, led by Dr. Jason S Knight and Dr. Yu (Ray) Zuo.

NEW EPISODE! Jason S Knight joins the podcast to break down the evolving science of antiphospholipid syndrome & its treatment. From antibodies to clinical trials—this is #APS like you’ve never heard it before. LISTEN NOW → acr.tw/3GxkWg8 ACR_Journals

🩸👀 We wrote a paper for Blood Advances about antiphospholipid syndrome (APS), platelets, and purinergic signaling, with an eye toward potential therapeutic targets. See the Replies for a link to the article...

Calprotectin may serve as a mechanistically informed biomarker for atherosclerotic cardiovascular disease, independent of traditional and contemporary cardiovascular risk factors and biomarkers. ja.ma/4054WbW Anand Rohatgi

#CatastrophicAPS affects <1% of #APS patients, causing rapid multi-organ #thrombosis. Mark’s story shows the value of coordinated care, incl. Yu (Ray) Zuo (Michigan Medicine). We’ve previously shared his work; we thank him for his work helping the APS community. cutt.ly/8rG4mPQT

❤️👀 Circulation Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling ahajournals.org/doi/10.1161/CI…